[Effects of Ligusticum wallichii on the plasma and CSF levels of dynorphin A1-13 in rabbits under acute experimental cerebral ischemia].
By occluding the bilateral carotid arteries of rabbits to produce bilateral partial cerebral ischemia, and by using radioimmunoassays to measure the levels of dynorphin A1-13 like immunoreactivity (ir-Dyn A1-13) in plasma and cerebrospinal fluid (CSF), the authors find that the levels of ir-Dyn A1-13 in plasma and CSF have significantly increased (P less than 0.01) after cerebral ischemia appears. The result of the Ligusticum wallichii Franch (Ligusticum) pretreatment to the test-group shows a definite improvement of the changes of ir-Dyn A1-13 levels in plasma and CSF. The severity of brain ischemic damage and neurologic dysfunction in Ligusticum-treated animals is lighter than that of saline-treated group, too. In this study, some new approaches are explored to explain the pathophysiology of cerebral ischemia and the mechanisms by which Ligusticum prevents and treats cerebral ischemia.
Liu
Z
Z
Department of Neurology, Changhai Hospital, Shanghai.
Shi
Y
Y
D000818:Animals; D002545:Brain Ischemia / Q000097:blood / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D004399:Dynorphins / Q000097:blood / Q000134:cerebrospinal fluid / Q000378:metabolism*; D005260:Female; D008297:Male; D010446:Peptide Fragments / Q000097:blood / Q000134:cerebrospinal fluid / Q000378:metabolism*; D011817:Rabbits
D004365:Drugs, Chinese Herbal; D010446:Peptide Fragments; C026843:dynorphin (1-13); D004399:Dynorphins